Bone pain is a common complication for patient with bone metastases from prostate, breasts, lung and renal cancers. Samarium-153 EDTMP (Ethylenediamine-N,N,N’,N’-tetrakis(methylene phosphonic acid)) is one of the most widely used radiopharmaceutical for the treatment of metastatic bone pain. Labelling of EDTMP with 186Re have been carried out with high radiochemical purity and this complex was stable up to 8 days . Biodistribution pattern of the injected this complex in mice indicates that the accumulated optimum activity in the bone was obtained after 24 hours post injection. Rhenium-186 EDTMP complex contents in the blood reach an optimum activity after 5 minutes and decrease drastically at 1 hours post injection. The complex showed major renal clearance up to 38 % as perrhenate ion within 24 hours after injection. In vitro protein binding investigation showed that 45-50 % of the compound bound to the plasma proteins. Rhenium-186 EDTMP revealed strong binding to hidroxyapatite and stable up to 2 days. Sterility and pyrogenicity test indicated that the compound were sterile and pyrogen free.
Key words : 186Re-EDTMP, bone, radiochemical purity, biodistribution
A. H.Gunawan, A. Mutalib, S. Aguswarini, Karyadi, S. Bagiawati, Abidin
Pusat Pengembangan Radioisotop dan Radiofarmaka - BATAN
Key words : 186Re-EDTMP, bone, radiochemical purity, biodistribution
A. H.Gunawan, A. Mutalib, S. Aguswarini, Karyadi, S. Bagiawati, Abidin
Pusat Pengembangan Radioisotop dan Radiofarmaka - BATAN
